Welcome to our dedicated page for Metsera news (Ticker: MTSR), a resource for investors and traders seeking the latest updates and insights on Metsera stock.
Metsera, Inc. (formerly NASDAQ: MTSR) generates a distinctive news profile at the intersection of biotechnology, obesity therapeutics, and large-cap pharmaceutical dealmaking. As a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, Metsera has issued frequent updates on its pipeline programs, particularly MET-097i, a fully biased, ultra-long acting GLP-1 receptor agonist with potential for monthly dosing. News coverage has highlighted Phase 2b results from the VESPER-1 and VESPER-3 trials, including dose-dependent weight loss and detailed gastrointestinal tolerability data in participants with overweight or obesity without type 2 diabetes.
Another major theme in MTSR news has been strategic transactions. Filings and press releases describe Metsera’s entry into an Agreement and Plan of Merger with Pfizer, subsequent amendment of the merger terms, and competing unsolicited proposals from Novo Nordisk A/S that were deemed “Superior Company Proposals” by Metsera’s Board. News items track the evolution of these offers, changes to cash consideration and contingent value rights (CVRs), and related litigation between Metsera and Pfizer over deal terms and regulatory considerations.
For readers following MTSR-related developments, this news stream includes: clinical trial milestones for MET-097i and its combination, oral, and prodrug programs; regulatory and antitrust steps such as early termination of the Hart-Scott-Rodino waiting period; Board determinations regarding competing bids; and the ultimate completion of Pfizer’s acquisition of Metsera and the resulting delisting of MTSR from the Nasdaq Global Select Market. Investors, analysts, and healthcare observers can use this page to review how Metsera’s scientific progress and transaction process unfolded over time.
Metsera (NASDAQ: MTSR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its obesity and metabolic disease pipeline. The company's lead candidate MET-097i, a monthly GLP-1 receptor agonist, demonstrated promising Phase 2a results with up to 11.3% mean placebo-subtracted weight loss after 12 weekly doses.
Financial highlights include completion of an IPO raising $316.2 million, extending runway into 2027. Year-end cash position was $352.4 million. Full-year 2024 results showed R&D expenses of $107.5 million and G&A expenses of $26.8 million, with a net loss of $209.1 million.
Key pipeline developments include:
- Multiple Phase 2b trials for MET-097i with readouts expected mid-2025
- MET-233i Phase 1 program progressing with data expected mid-2025
- Oral formulation studies for MET-224o and MET-097o advancing
- Initiation of IND-enabling studies for MET-815i
Metsera (MTSR), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, has announced its participation in TD Cowen's 45th Annual Health Care Conference.
The company's CEO, Whit Bernard, is scheduled to deliver a presentation on Tuesday, March 4, 2025, from 1:10 to 1:40 p.m. ET. Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & News section at investors.metsera.com. The presentation recording will remain accessible for 90 days after the event.
Metsera (NASDAQ: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has successfully completed its initial public offering (IPO). The company sold 15,277,778 shares at $18.00 per share, with underwriters exercising their full option to purchase an additional 2,291,666 shares at the same price.
The total gross proceeds from both the initial shares and additional shares amounted to $316.2 million, before deducting underwriting discounts and other expenses. The company's common stock is now trading on the Nasdaq Global Select Market under the ticker symbol 'MTSR'. BofA Securities, Goldman Sachs & Co. , Evercore ISI, Guggenheim Securities, and Cantor served as joint bookrunners for the offering.
Metsera (Nasdaq: MTSR), a clinical-stage biotech company focused on developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides for obesity treatment, has announced the pricing of its initial public offering. The company is offering 15,277,778 shares of common stock at $18.00 per share, expecting to raise gross proceeds of approximately $275.0 million before deducting underwriting costs and expenses.
Trading is set to begin on the Nasdaq Global Select Market under ticker 'MTSR' on January 31, 2025, with the offering expected to close on February 3, 2025. Metsera has granted underwriters a 30-day option to purchase up to an additional 2,291,666 shares at the IPO price. BofA Securities, Goldman Sachs, Evercore ISI, Guggenheim Securities, and Cantor are serving as joint bookrunners.